Zobrazeno 1 - 10
of 1 376
pro vyhledávání: '"D. Watt"'
Autor:
Afsana Afroz, Bodrun Naher Siddiquea, Hasina Akhter Chowdhury, Timothy Nw Jackson, Andrew D Watt
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 18, Iss 4, p e0012080 (2024)
BackgroundSnakebite envenoming represents a significant and often neglected public health challenge, particularly in rural communities across tropical and subtropical regions. An estimated 1.2-5.5 million people are envenomed by snakebites annually.
Externí odkaz:
https://doaj.org/article/9178eb46f2f74b18b601ba9550d496ee
Autor:
Kristina Andrijauskaite, Rafael J. Veraza, Riley P. Lopez, Zach Maxwell, Isabella Cano, Exal E. Cisneros, Israel J. Jessop, Maria Basurto, George Lamberson, Michelle D. Watt, Joseph Nespral, Masahiro Ono, Leonid Bunegin
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
IntroductionHeart transplant remains the gold standard treatment for patients with advanced heart failure. However, the list of patients waiting for a heart transplant continues to increase. We have developed a portable hypothermic oxygenated machine
Externí odkaz:
https://doaj.org/article/580ff6c92bf7437aaa688c4bf9ea2d2a
Publikováno v:
Hepatology Communications, Vol 6, Iss 9, Pp 2227-2237 (2022)
Abstract Growth hormone and its mediator insulin‐like growth factor‐1 exert their effect on different organs and control various physiologic metabolic processes. Adult growth hormone deficiency (AGHD) presents with one or more components of metab
Externí odkaz:
https://doaj.org/article/2cc2e27f6d144181b9e44b1a99676475
Publikováno v:
Hepatology Communications, Vol 6, Iss 6, Pp 1250-1261 (2022)
Post‐transplant diabetes mellitus (PTDM) is a significant contributor to morbidity and mortality in liver transplant recipients (LTRs). With concurrent comorbidities and use of various immunosuppression medications, identifying a safe and personali
Externí odkaz:
https://doaj.org/article/c2bde4d764304d9c9f961bbc39018c19
Autor:
Lydia A. Mercado, MD, Harpreet K. Bhangu, MD, Esteban Calderon, MD, Amit K. Mathur, MD, Bashar Aqel, MD, Kaitlyn R. Musto, BSc, Kymberly D. Watt, MD, Charles B. Rosen, MD, Candice Bolan, MD, Jordan D. LeGout, MD, C. Burcin Taner, MD, Denise M. Harnois, DO, Kristopher P. Croome, MD, MS
Publikováno v:
Transplantation Direct, Vol 8, Iss 11, p e1392 (2022)
Background. With donation after circulatory death (DCD) liver transplantation (LT), the goal of the recipient implantation procedure is to minimize surgical complexity to avoid a tenuous environment for an already marginal graft. The presence of port
Externí odkaz:
https://doaj.org/article/b32d7fcfe42f47098d543a3cb68ae0d0
Autor:
Emmanuel A. Tsochatzis, Kymberly D. Watt, Lisa B. VanWagner, Elizabeth C. Verna, Annalisa Berzigotti
Publikováno v:
Journal of Hepatology. 78:1089-1104
Liver transplant(ation) (LT) is the most effective treatment for patients with decompensated liver disease. The increasing prevalence of obesity and type 2 diabetes and the growing number of patients with non-alcoholic fatty liver disease being evalu
Publikováno v:
Psychiatry, Psychology and Law. :1-21
Autor:
Hector R. Cajigas, Charles D. Burger, Rodrigo Cartin-Ceba, Hilary DuBrock, Karen Swanson, Hugo E. Vargas, Andrew P. Keaveny, Kymberly D. Watt, Michael Krowka
Publikováno v:
Mayo Clinic Proceedings. 97:2236-2247
To explore clinical characteristics, risk profiles, and outcomes of patients with portopulmonary hypertension (PoPH) who have contraindications to liver transplant (LT).From the largest US single-institution registry of patients with PoPH, we analyze
Autor:
MacLean P. Nasrallah MD, PhD, Zev A. Binder MD, PhD, Derek A. Oldridge MD, PhD, Jianhua Zhao PhD, FACMG, David B. Lieberman MS, CGC, Jacquelyn J. Roth PhD, Christopher D. Watt MD, PhD, Shrey Sukhadia MS, Eva Klinman PhD, Robert D. Daber PhD, Arati Desai MD, Steven Brem MD, Donald M. O’Rourke MD, Jennifer J. D. Morrissette PhD
Publikováno v:
Academic Pathology, Vol 6 (2019)
Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and treatment. Our neuro-oncology group has developed a data-driven, institutional consensus gu
Externí odkaz:
https://doaj.org/article/d2e4dd6467f7414987f25784371d72bc
Autor:
Alexander E. Perl, Catherine C. Smith, Martin Carroll, Neil P. Shah, Selina M. Luger, Aaron C. Logan, Safoora Deihimi, Lisa H.F. McGary, Cheryl A.C. Peretz, RosaAnna DeFilippis, Elisabeth A. Lasater, Saurabh Asthana, Christopher D. Watt, Robert Durruthy-Durruthy, Maurizio Pellegrino, Dennis J. Eastburn, Jennifer J.D. Morrissette, Eunice S. Wang, Jonathan Canaani, Timothy Ferng, Christine M. McMahon
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib is not curative, and response duration is limite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9342e80b4dcae04c4e27e5d1a7598d23
https://doi.org/10.1158/2159-8290.c.6548240.v1
https://doi.org/10.1158/2159-8290.c.6548240.v1